| Date | Title | Description |
| 10.03.2026 | Bright spots in tackling AMRs, but drug-resistance outpaces pharma industry efforts: Report | - |
| 25.02.2026 | ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen | ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced positive 12-month interim efficacy and tolerability data from the phase IIb EMBRACE study.1 In adults livin... |
| 25.01.2026 | GSK Bolsters Immunology Pipeline with $2.2B RAPT Acquisition | GSK made a significant strategic acquisition. The pharmaceutical giant purchased US biotech RAPT Therapeutics for $2.2 billion. This deal secures global rights to ozureprubart. Ozureprubart is an experimental, long-acting drug. It targets I... |
| 20.01.2026 | GSK to acquire US biotech group for $2.2bn | FTSE 100 giant GSK has reached an agreement to acquire US based biotech group Rapt Therapeutics.
The deal values the company, which develops therapies for treating people with inflammatory and immunologic diseases, at $2.2bn (£1.6bn), and m... |
| 26.09.2025 | European, Asian drugmaker shares drop after Trump imposes tariffs | European, Asian drugmaker shares drop after Trump imposes tariffs
By Gregor Hunter and Andrew SilverSeptember 26, 20256:58 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Item 1 of 2 The logo of... |
| 08.09.2025 | Regulatory Landscape of Digital Health in Asia | Share
Share
Share
Share
Email
Digital health is rapidly evolving across Asia and transforming what patients, healthcare providers, and health authorities think about care delivery. The emergence of AI, reimbursement frameworks, and pandemic... |
| 02.07.2025 | BioVersys enters into research and license option agreement with Shionogi & Co |
The joint research teams of BioVersys and Shionogi & Co aim to deliver clinical candidates and back-up molecules during the research collaboration period. Shionogi will have the exclusive option to license a selected number of molecule... |
| 08.05.2025 | Raya Therapeutic Appoints Juan Carlos Gomez MD, MBA, Chief Medical Officer of Shionogi and Company to its Board | Company Logo
Dr. Gomez brings extensive neuroscience and orphan disease development experience to Raya as it plans multiple clinical trials in 2026.
MONTREAL, QUEBEC, CANADA, May 8, 2025 /EINPresswire.com/ -- Raya Therapeutic Inc., (“Raya”)... |
| 08.01.2025 | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing | Third Rock-backed Maze Therapeutics reveals profit in US IPO filing
By ReutersJanuary 7, 202511:00 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
The Nasdaq logo is displayed at the Nasdaq Mark... |
| 31.08.2024 | AP News: японское правительство продвигает четырёхдневную рабочую неделю, но компании принимают её неохотно | Японское правительство вот уже три года поддерживает введение сокращённой рабочей недели. Тем не менее, по данным AP News, концепция приживается крайне медленно: всего около 8% компаний в Японии разрешают сотрудникам брать три или более вых... |
| 07.06.2024 | FunPep Co., Ltd. Notice regarding the latest development status of allergy vaccines | - |
| 07.06.2024 | FunPep Co., Ltd. Notice regarding the latest development status of allergy vaccines | FunPep Co., Ltd.
Notice regarding the latest development status of allergy vaccines ……
FunPep Co., Ltd. (Headquarters: Ibaraki City, Osaka Prefecture, President: Toshimi Miyoshi) has announced the following regarding non-clinical trial data... |
| 09.05.2024 | Approximately USD 10.8 Million Invested in New Drug Development for Malaria and NTDs in Partners Including Japanese Pharma Shionogi, Mitsubishi Tanabe, and Eisai and Europe-Based Institutions | TOKYO, May 9, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.64 billion (USD 10.8 million1) in four projects for the development of new drugs for malaria an... |
| 14.02.2024 | FRONTEO Co., Ltd. FRONTEO and Shionogi & Co. enter into a strategic business partnership agreement regarding the dementia/depression diagnosis support AI program business | - |
| 14.02.2024 | FRONTEO Co., Ltd. FRONTEO and Shionogi & Co. enter into a strategic business partnership agreement regarding the dementia/depression diagnosis support AI program business | FRONTEO Co., Ltd.
FRONTEO and Shionogi & Co. enter into strategic business alliance agreement regarding AI program business to support diagnosis of dementia and depression
……
FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President ... |
| 15.01.2024 | Shionogi & Co., Ltd. Shionogi & Co., Ltd. will hold an online seminar on data science again this year! “SHIO NOGI DATA SCIENCE FES 2024” | - |
| 15.01.2024 | Shionogi & Co., Ltd. Shionogi & Co., Ltd. will hold an online seminar on data science again this year! “SHIO NOGI DATA SCIENCE FES 2024” | Shionogi Pharmaceutical Co., Ltd.
Shionogi & Co., Ltd. will hold an online seminar on data science again this year! “SHIONOGI DATA SCIENCE FES 2024”
……
Shionogi & Co., Ltd. (Headquarters: Chuo-ku, Osaka; Representative Director, Cha... |
| 02.11.2023 | 4DIN 塩野義製薬株式会社の新型コロナウイルス感染症(COVID-19)治療薬の電子カルテデータを用いた研究実施を支援 | 医療機関と製薬企業との共同研究を通じて、臨床情報分析支援プラットフォームSIMPRESEARCH®︎を用いて医療情報を活用することにより研究や試験数の増加、患者リクルートメント効率化などを支援している株式会社4DIN(本社：東京都港区、代表取締役CEO：高橋 精彦、以下4DIN)は、2023年4月からスタートした塩野義製薬株式会社による新型コロナウイルス感染症(COVID-19)治療薬「エンシトレルビル フマル酸（日本での製品名：ゾコーバ®︎錠125mg、以下 エンシトレルビ... |
| 11.10.2023 | 「SHIONOGI感染症Weeks」の開催に関するお知らせ | 塩野義製薬株式会社（本社：大阪市中央区、代表取締役会長兼社長CEO：手代木 功、以下「SHIONOGI」または「当社」）は、感染症について社会の皆さまと共に考え、共にたたかうための「SHIONOGI感染症Weeks」を、10月10日（火）～11月10日（金）の期間で開催することをお知らせいたします。
世界中の人々の生活や社会経済に大きな影響をもたらした新型コロナウイルス感染症（以下、「COVID-19」）は、世界的にも感染者数、死亡者数が減少し（＊1）、日本を含め多くの国で... |
| 21.02.2023 | Japanese corporations want to do business with European startups – here's how to get in on it | From Fujifilm to Mitsubishi, major Japanese corporations are looking to boost their innovations, and they're looking to Europe to do just that.
On March 7-9th, Japanese corporations will be reverse-pitching – presenting themselves to startu... |
| 28.09.2022 | Covid-19 roundup: Shionogi’s antiviral pill hits the mark; Ocugen strikes deal for intranasal vaccine | Japanese pharma Shionogi’s Covid-19 antiviral against Omicron passed its Phase III trial in Asia, meeting its primary endpoint.
The drug, a protease inhibitor known as ensitrelvir, was administered daily for five days and... |
| 27.09.2022 | Updated: Study identifies Covid-19 patients with mutations indicating remdesivir resistance | As the bivalent booster season kicks off in earnest, a new study published yesterday from NYU researchers identifies two cases of mutated coronavirus resistant to Gilead’s remdesivir in immunocompromised individual... |
| 26.09.2022 | Covid-19 roundup: Pfizer, BioNTech kick off EUA dance for teen bivalent shot; Report details slow US booster rollout | While Moderna’s vaccine has been sent off for an EUA for teens and preteens, its rivals, Pfizer and BioNTech, are right on its heels with an EUA submission of their own.
On Monday, both companies announced that they finished s... |
| 26.09.2022 | Valneva’s second-gen Covid vaccine plans up in the air as it looks for partner | Valneva has had a rocky couple of months.
While European authorities recommended its non-mRNA Covid shot for primary vaccination in adults in late June, the European Commission announced a month later that it was cut... |
| 23.09.2022 | Covid-19 roundup: Moderna sends in EUA for bivalent teen booster; US trimming Pfizer/BioNTech donations | Though Moderna’s bivalent vaccine to counter the Omicron variant has cleared the initial hurdles in getting FDA authorization, the vaccine maker is moving on to the next step.
On Twitter, the company announced on Friday... |
| 04.08.2022 | Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million | Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commerc... |
| 16.03.2022 | Shionogi Pharmaceutical Announced the results of comprehensive efforts in the “Mother to Mother SHIONOGI Project”, a support activity for mothers and children in Kenya. | Shionogi Pharmaceutical Co., Ltd.
Announcement of the results of comprehensive efforts of “Mother to Mother SHIONOGI Project”, a support activity for mothers and children in Kenya
-Contributing to improving the health of Maasai mothers and ... |
| 10.02.2022 | Shionogi Announces the Conclusion of a Contract for the Establishment of a Research Department for Mucosal Vaccines with Chiba University Hospital | OSAKA, Japan - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO:
Isao Teshirogi, Ph.D.; hereafter 'Shionogi') are pleased to announce the conclusion of a contract for the establishment of a research department with Chi... |
| 08.02.2022 | SHIMADZU : and SHIONOGI establishes joint venture AdvanSentinel- Solving social issues via public health risk assessment, including wastewater surveillance - | About Shionogi & Co., Ltd.
Shionogi is committed to "protect people worldwide from the threat of infectious diseases" as our key focus. We are not limiting ourselves to the research and development of therapeutics, but are als... |
| 07.02.2022 | Shionogi : Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622 | Press Release
Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for
the COVID-19 Therapeutic Drug S-217622
OSAKA, Japan, February, 7, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and
CEO: Isao Teshi... |
| 31.01.2022 | Shionogi : Presents Clinical Trial Results of the COVID-19 Therapeutic Drug S-217622 | Press Release
Shionogi Presents Clinical Trial Results of
the COVID-19 Therapeutic Drug S-217622
OSAKA, Japan, January, 31, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and
CEO: Isao Teshirogi, Ph.D.; hereafter &quo... |
| 20.01.2022 | Shionogi : Notice Regarding the Progress of S-217622 to Fight COVID-19 | Press Release
Notice Regarding the Progress of S-217622 to Fight COVID-19
OSAKA, Japan, January, 20, 2022 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and
CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") annou... |
| 06.01.2022 | Shionogi Announces Commitment to Fight COVID-19 | Osaka, Japan - Shionogi & Co., Ltd. (President & CEO:
Isao Teshirogi, Ph.D., hereafter: 'Shionogi') has been continuing efforts on an oral antiviral drug and a preventive vaccine for COVID-19. The progress of each of these efforts c... |
| 27.12.2021 | SHIONOGI : Announces a Commercialization Agreement with SUSMED for a Digital Therapeutic App for Insomnia | Press Release
SHIONOGI Announces a Commercialization Agreement with SUSMED for
a Digital Therapeutic App for Insomnia
OSAKA, Japan, December, 27, 2021 - Shionogi & Co., Ltd. (Headquarters: Osaka, Japan; President
and CEO: Isao Teshirogi... |
| 20.12.2021 | Shionogi : Announces Commitment to Address the Omicron Variant of SARS-CoV-2 | Press Release
Shionogi Announces Commitment to Address the Omicron Variant of
SARS-CoV-2
Osaka, Japan, December 20, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and
CEO: Isao Teshirogi, Ph.D.; hereafter "Shiono... |
| 14.12.2021 | SHIONOGI Announces Positive Results from a Phase 2 Clinical Trial of the Regeneration Inducing Medicine S-005151 in Patients with Acute Ischemic Stroke | OSAKA - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO:
Isao Teshirogi, Ph.D.; hereafter 'Shionogi') announced that the primary endpoint in a Phase 2 clinical trial of redasemtide in patients with acute ischemic stro... |
| 13.12.2021 | SHIONOGI : Announces Positive Results from a Phase 2 Trial of the Regeneration Inducing Medicine S-005151 (Redasemtide) with Acute Ischemic Stroke | Press Release
SHIONOGI Announces Positive Results from a Phase 2 Clinical Trial of the
Regeneration Inducing Medicine S-005151 (Redasemtide) in Patients
with Acute Ischemic Stroke
OSAKA, Japan, December, 13, 2021 - Shionogi & Co., Ltd. ... |
| 07.12.2021 | Shionogi : Announces Launch of Mutational Analysis Services for Wastewater-based Epidemiological Surveillance of the Novel Coronavirus | Press Release
Shionogi Announces Launch of Mutational Analysis Services for Wastewater-based Epidemiological Surveillance of the Novel Coronavirus
OSAKA, Japan, December 7, 2021 - Shionogi & Co., Ltd. (hereafter "Shionogi") an... |
| 30.11.2021 | Shionogi : Notice Regarding Reorganization of Subsidiary through Company Merger | Press Release
Notice Regarding Reorganization of Subsidiary through Company Merger
OSAKA, Japan, November, 30, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President
and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi&qu... |
| 22.10.2021 | Shionogi : Section 4 Shionogi's Value-Promoting System | Section 4 Shionogi's Value-Promoting System
Corporate Governance
Shionogi has chosen to establish a company with a board of corporate auditors because it will enable the smooth functioning of the management monitoring system by enhancing th... |
| 22.10.2021 | Shionogi : Data Section | Data Section
11-Year Financial Summary
Third Medium-Term Business Plan SONG for the Real Growth Grow as a drug discovery-based
Progress toward global growth pharmaceutical company
(FY2014-September FY2016)
JGAAP 2011 2012 2013 2014 2015 201... |
| 22.10.2021 | Shionogi : Section 2 New Growth—Shionogi's Transformation Strategy [ | Section 2 New Growth-Shionogi's Transformation Strategy
Special FeatureShionogi's Further Evolution
A Turbulent Fiscal 2020 and Creating Our Disease Strategy Vision
Fiscal 2020 was a year in which COVID-19 brought about dramatic technologic... |
| 22.10.2021 | SHIONOGI : Integrated Report 2021 | SHIONOGI INTEGRATED REPORT 2021
YEAR ENDED MARCH 31, 2021
Building Innovation Platforms to Shape the Future of Healthcare
CONTENTS
2 Our Philosophy
Section 1
Shionogi's Strengths Cultivating the Future
4 Special Feature COVID-19
6 Message f... |
| 11.10.2021 | The first-ever COVID-19 pill may be just weeks away. A handful of other pills, inhalers, and nasal sprays also show promise. | A man holds a capsule. Photographer, Basak Gurbuz Derman/Getty Images
Treating COVID-19 could be simpler soon, thanks to the next generation of treatments.
These could come in the form of pills, nasal sprays, or inhalers.
On Monday, Merck a... |
| 29.09.2021 | SHIONOGI announces out-licensing agreement with ViiV Healthcare to develop third-generation HIV integrase inhibitor, S-365598, with potential for ultra long-acting dosing intervals | OSAKA, Japan - Shionogi & Co., Ltd. (hereafter 'Shionogi') announced that it has entered into an out-licensing agreement with ViiV Healthcare (hereafter 'ViiV'), the global specialist HIV company majority owned by GlaxoSmithKline ('GSK'... |
| 29.09.2021 | Shionogi : to Present In Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETCROJA® (cefiderocol) Against Gram-Negative Pathogens | Shionogi & Co., Ltd. (hereafter “Shionogi”) today announces that 11 abstracts on FETCROJA® (cefiderocol) will be shared at IDWeek. The meeting will take place virtually from September 29 - October 3, 2021.
“The data presented at IDWeek ... |
| 28.09.2021 | Shionogi to Present In Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETROJA® (cefiderocol) Against Gram-Negative Pathogens | Shionogi & Co., Ltd. (hereafter “Shionogi”) today announces that 11 abstracts on FETROJA® (cefiderocol) will be shared at IDWeek. The meeting will take place virtually from Sept. 29 – Oct. 3, 2021.
“The data presented at IDWeek undersco... |
| 28.09.2021 | SHIONOGI : announces out-licensing agreement with ViiV Healthcare to develop third-generation HIV integrase inhibitor, S-365598. | Press Release
SHIONOGI announces out-licensing agreement with ViiV Healthcare
to develop third-generation HIV integrase inhibitor, S-365598,
with potential for ultra long-acting dosing intervals
S-365598 aims to build on the success of dolu... |
| 02.08.2021 | Shionogi : 1Q Presentation material | 1st Quarter of Fiscal 2021 Financial Results
Conference Call
August 2, 2021
Shionogi & Co., Ltd.
Agenda
Overview of Q1 FY2021 Financial Results (P.3-9)
Main Activities and Achievements in Q1 FY2021(P.10-19)
2
1. Overview of Q1 FY2021 Fi... |
| 20.07.2021 | Shionogi : and HanaVax Enter into a License Agreement for COVID-19 Vaccine Development Using Cationic Nanogel Delivery System | Osaka and Tokyo, Japan - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO:
Isao Teshirogi, Ph.D.; hereafter 'Shionogi') and HanaVax Inc. (Head Office: Tokyo, Japan; President & CEO: Mizuhiro Ishimaru; hereafter '... |
| 14.07.2021 | SHIONOGI : GARDP, CHAI and Shionogi announce MOU to increase access to antibiotic to treat antimicrobial resistant infections in low- and middle-income countries | The Global Antibiotic Research and Development Partnership (GARDP), the Clinton Health Access Initiative (CHAI) and Shionogi & Co., Ltd. announced a Memorandum of Understanding (MOU) to accelerate access, including in low- and middle-in... |
| 22.06.2021 | Shionogi : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan | Press Release
Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
OSAKA, Japan, June 22, 2021 - Shionogi & Co., Ltd. (hereafter "Shionogi") announced that, at the meeting of its Board of Directors held ... |
| 16.04.2021 | SHIONOGI & CO., LTD.
Shionogi : Agreement of Joint Sales with LumiraDx Japan for Coronavirus Antigen test agent and diagnostic instrument in Japan | Press Release
Shionogi Announces Agreement of Joint Sales with
LumiraDx Japan Co., Ltd. for Novel Coronavirus Antigen test agent
"LumiraDx SARS-CoV-2 Ag Test Strip"
and diagnostic instrument in Japan
OSAKA, Japan, April, 16, 2021 ... |
| 27.07.2020 | SHIONOGI & CO., LTD.
Shionogi : Execution of the Agreements on the Establishment of the Joint Ventures with Ping An and the Disposal of Treasury Shares by Way of Third-Party Allot | Press Release
Notice Regarding the Execution of the Agreements on the Establishment of
the Joint Ventures with Ping An and the Disposal of Treasury Shares
by Way of Third-Party Allotment
OSAKA, Japan, July 27, 2020 - Shionogi & Co., Ltd... |
| 09.01.2019 | Tetra Inks Deal with Shionogi to Support Fragile X, Alzheimer’s R&D | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
The lead drug of Tetra Discovery Partners is already in mid-stage clinical studies as a treatment for the rare Fragile X Syndrome. But the Grand Rapids, MI, biotech says its d... |
| 19.06.2018 | Japanese pharma company joins £1.4m seed funding round for Nemesis Bioscience | Japanese pharma company joins £1.4m seed funding round for Nemesis Bioscience
19-06-2018
Nemesis Bioscience today announced the completion of a seed funding round of £1.4M from a syndicate of new investors including Shionogi & Co Ltd, C... |
| 17.02.2012 | ACOR’s Neuronex acquisition worth up to $133M; hinges on epilepsy drug | Hawthorne, New York-based Acorda said in regulatory filings that Neuronex’s nasal diazepam, referred to as DZNS, fits into the company’s neurology drug portfolio. Acorda’s top-selling drug is multiple sclerosis treatment Amphyra, which gene... |
| 21.10.2011 | CNS therapies firm Aerial BioPharma launches $12M fundraising round | Khayrallah’s former company, Durham, North Carolina-based Addrenex was founded in 2006 supported by angel investment and loans from the North Carolina Biotechnology Center. The company’s lead drug candidate was Clonicel, a compound being de... |
| 09.03.2009 |
Victory Pharma Raises $45M
| San Diego-based Victory Pharma has raised $45M in an equity financing round, the firm said Monday. The round was led by Essex Woodlands Health Ventures, and also included prior investor Ampersand Ventures. According to Victory Pharma, Scott... |
| 09.03.2009 | Victory Pharma Announces US$45 Million Equity Financing | Mar 09 2009
SAN DIEGO, California—Victory Pharma, Inc. (“Victory” or “the Company”), a privately held specialty pharmaceutical company, today announced that it has closed on a US$45 million equity financing facility led by Essex Woodlands ... |
| - | CNS therapies firm Aerial BioPharma launches $12M fundraising round | The team that built Addrenex Pharmaceuticals from startup into a $29 million exit without raising a dime of venture capital is making another run with a new company – Aerial BioPharma.
Morrisville, North Carolina-based Aerial is focused on ... |
| - | ACOR’s Neuronex acquisition worth up to $133M; hinges on epilepsy drug | Central nervous system therapies company Neuronex is being acquired by Acorda Therapeutics (NASDAQ:ACOR) in a deal valued at up to $133 million, yielding to Acorda a novel epilepsy treatment nearly ready for filing with the U.S. Food and Dr... |
